Aldeyra Stock Plunges as FDA Rejects Reproxalap Dry Eye Drug in Major Setback

Aldeyra Therapeutics receives FDA Complete Response Letter rejecting reproxalap for dry eye disease due to insufficient efficacy. No safety issues. ALDX shares crash.